NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026 NeoGenomics, Inc. misses on earnings ...

Valuation positioning and trading range stability align with broader nasdaq index sentiment. NeoGenomics, Inc. (NASDAQ:NEO) ...

NeoGenomics Inc (NASDAQ:NEO) on Tuesday posted fourth-quarter results that topped Wall Street estimates, though shares declined sharply in early trading as investors weighed the company’s growth ...

In February 2026, NeoGenomics, Inc. announced PanTracer Pro, a new test that combines comprehensive genomic profiling, ...

Customer satisfaction remained a standout, with a Net Promoter Score of 79 and further improvement in 2025, indicating deep loyalty among clinicians. The number of pathologists and oncologists ...

FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, ...

Analysts expect earnings of 4 cents a share on revenue of $188.1 million, representing modest sequential improvement from the ...

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

Kendra Webster with NeoGenomics, Inc. The floor is yours. With me today to discuss the results are Anthony P. Zook, Chief ...